Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:32 2024-05-21 am EDT			5-day change	1st Jan Change
622.5 ^DKK	+3.75%		-2.05%	+66.80%

May. 16	Nordic Stocks Declined Thursday; Zealand Pharma Took Biggest Hit	DJ
May. 16	Transcript : Zealand Pharma A/S, Q1 2024 Earnings Call, May 16, 2024

Zealand Pharma A/S Provides Earnings Guidance for the Fiscal Year 2022

March 10, 2022 at 09:00 am EST

Zealand Pharma A/S provided earnings guidance for the fiscal year 2022. For the period, the company expects net product revenue from the sales of its commercial products of DKK 235.0 million +/-10% compared to 2021 of DKK 184.0 million.

Latest news about Zealand Pharma A/S

Nordic Stocks Declined Thursday; Zealand Pharma Took Biggest Hit	May. 16	DJ
Transcript : Zealand Pharma A/S, Q1 2024 Earnings Call, May 16, 2024	May. 16
Zealand Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 16	CI
U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year	Apr. 04	DJ
Zealand Pharma A/S Approves Appointments to the Board	Mar. 20	CI
Global markets live: Robinhood, Dollar General, KKR, Boeing, Oracle...	Mar. 14
Zealand Pharma A/S Announces Board Changes	Mar. 13	CI
Nordic Stocks Dropped Monday; Zealand Pharma Took Biggest Hit	Mar. 11	DJ
Nordic Stocks Moved Upward Thursday; Zealand Pharma Topped Leaders	Mar. 07	DJ
US Futures, European Stocks Mostly Down	Feb. 28	DJ
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27	RE
Transcript : Zealand Pharma A/S, 2023 Earnings Call, Feb 27, 2024	Feb. 27
US Futures Flat, European Stocks Mostly Rise	Feb. 27	DJ
Zealand Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Zealand Pharma Shares Surge 41% on 'Positive' Results From Phase 2 Study of Weight Loss Drug Survodutide	Feb. 26	MT
Nordic Shares Declined Monday; Embracer Group Series B Posted Biggest Loss	Feb. 26	DJ
European Equities Close Mostly Lower in Monday Trading; UK Regulator Probes Homebuilders for Anti-Competitive Practices	Feb. 26	MT
Boehringer eyes obesity, fatty liver drug launch in 2027 or 2028	Feb. 26	RE
BOEHRINGER EXEC BROUILLON TELLS REUTERS IT IS NOT CLEAR YET WHET…	Feb. 26	RE
Zealand Pharma: positive results in NASH	Feb. 26	CF
Commodity-linked stocks drag European equities lower	Feb. 26	RE
Zealand shares surge on liver drug data from Boehringer pact	Feb. 26	RE
Zealand Pharma shares surge on liver disease drug trial data	Feb. 26	RE
US Futures, European Stocks Mostly Fall	Feb. 26	DJ
Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis	Feb. 26	CI

Chart Zealand Pharma A/S

Duration

Period

More charts

Company Profile

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.

Sector

Biotechnology & Medical Research

Calendar

2024-08-15 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Ratings for Zealand Pharma A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

600 DKK

Average target price

785.6 DKK

Spread / Average Target

+30.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZEALAND PHARMA A/S	+66.80%	5.44B
VERTEX PHARMACEUTICALS INCORPORATED	+7.69%	115B
REGENERON PHARMACEUTICALS, INC.	+12.72%	107B
BIONTECH SE	-13.24%	22.31B
ARGENX SE	-3.99%	21.6B
BEIGENE, LTD.	-6.35%	18.23B
WUXI APPTEC CO., LTD.	-39.93%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+6.75%	14.26B
SAREPTA THERAPEUTICS, INC.	+32.72%	12.37B
LEGEND BIOTECH CORPORATION	-28.62%	8.28B

Bio Therapeutic Drugs